

One Test Premium is generally more sensitive for early-stage cancers than Galleri

All Cancer		Lung		Liver		CRC		Pancreas						
Stage	OT-P	Galleri	Stage	OT-P	Galleri	Stage	OT-P	Galleri	Stage	OT-P	Galleri	Stage	OT-P	Galleri
All	62%	52%	All	51%	75%	All	89%	94%	All	72%	82%	All	93%	84%
I	44%	17%	I	33%	22%	I	86%		I	64%	43%	I	86%	62%
II	61%	40%	II	61%	80%	II	91%		II	80%	85%	II	96%	60%
III	77%	77%	III	53%	91%	III	100%		III	76%	88%	III	100%	86%
IV	86%	90%	IV	91%	95%	IV	100%		IV	100%	95%	IV	86%	96%
		Prostate		Ovary		Breast		Gastric						
Stage	OT-P	Galleri	Stage	OT-P	Galleri	Stage	OT-P	Galleri	Stage	OT-P	Galleri	Stage	OT-P	Galleri
All			All	76%	11%	All	74%	83%	All	19%	31%	All	33%	67%
I			I	100%		I	25%	50%	I	15%		I	27%	17%
II			II	58%		II	100%	80%	II	15%		II	50%	50%
III			III	89%		III	100%	87%	III	57%		III	80%	80%
IV			IV			IV	80%	95%	IV			IV		100%

OneTest Premium data is provided by BioInfra. Galleri data is taken from Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, Chung G, Clement J, Gao J, Hunkapiller N, Jamshidi A, Kurtzman KN, Seiden MV, Swanton C, Liu MC. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-1177. doi: 10.1016/j.annonc.2021.05.806. Epub 2021 Jun 24. PMID: 34176681. OneTest premium specificity is held at >98%, Galleri specificity is at 99.5%. This is case:control data for both tests.